Search
  • 网站搜寻
亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。
返回搜索结果

Drug screening for genetic disorders (Yissum)


总结

Human pluripotent stem cells (hPSC) genetic manipulation had been developed to establish models for human genetic disorders such as fragile X syndrome, Down syndrome, and Prader-Willi syndrome (and others) as well as some genetic cancers (such as retinoblastoma) and genetic diabetes (Mody1, Mody4)
Overall, the group has developed 15 disease models for 13 genetic disorders (complex disorders).
Numerous developmental diseases cannot be studied through animal models, nor by isolating cells from patients. In such cases, hPSC can be used as a complementary model system that overcomes these impediments.
We propose using these models as platforms for screening small molecules to treat these genetic disorders, as well as validating their potential therapy for human developmental genetic disorders.Human pluripotent stem cells (hPSC) may give rise to most human body cell types, and as such they hold the promise to change the face of biomedical research and therapy
We demonstrated genetic manipulation of hPSC to establish models for human genetic disorders.
Using these models, we have unravelled the molecular basis of genetic disorders, and identified a paradigm treatment for disorders such fragile X syndrome and Lesch-Nyhan disease.


技术优势

Novel models for human developmental genetic disorders are used to unravel the molecular basis of the disorders and identified a paradigm treatment thereof.
A powerful high screening tool for small molecules to treat rare and genetic disorders.
We are currently gathering novel information on the basis of 13 genetic diseases, as well as developing new therapies to treat them.


技术应用

High throughput screening of small molecules for those indications
Rational selection of a drug based on the pathological mechanism of the disease in question.


ID号码

7-2015-3118


国家/地区

以色列

欲了解更多信息,请点击 这里
Business of IP Asia Forum
桌面版